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Abstract: 
 
The physical manifestations of neurofibromatosis type 1 (NF1) can cause chronic pain. This 
study investigated the impact of pain in youth with NF1 and plexiform neurofibromas (PNs) and 
its relationship to disease factors, social-emotional functioning, and quality of life (QOL) within 
a biopsychosocial framework. Caregivers of 59 children and adolescents with NF1 and PNs (6–
18 years), and 41 of these youth (10–18 years), completed questionnaires assessing social-
emotional functioning and QOL, including an item on pain interference. Measures of disease 
severity included total PN volume by percent body weight and number of disease complications. 
Both caregiver (73%) and self-report (59%) ratings indicated that pain interferes with the child's 
daily functioning despite 33% taking pain medication. Based on caregivers’ behavior ratings, 
more symptoms of anxiety and larger tumor volumes predicted greater pain interference, while 
greater pain interference, worse depressive symptoms, and more disease complications predicted 
poorer QOL. As rated by adolescents, more symptoms of anxiety predicted greater pain 
interference, while greater pain interference and social stress predicted poorer QOL. Further, 
social-emotional problems mediate the relationship between pain interference and QOL. Thus, 
pain interferes with daily functioning in the majority of youth with NF1 and PNs even when 
using pain medication. The impact of pain interference, disease severity, and particularly social-
emotional problems on QOL highlights the interaction between physical and psychological states 
in NF1. Future research and treatment of pain in this population should utilize a biopsychosocial 
approach and involve multidisciplinary therapies including psychological interventions that 
target social-emotional functioning. 
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Article: 
Introduction 
 
Neurofibromatosis type 1 (NF1) is one of the most common autosomal dominant genetic 
disorders, affecting approximately 1 in 3,000 [Friedman, 1999]. Individuals with NF1 have an 
increased risk of developing tumors of the central and peripheral nervous system, including 
plexiform neurofibromas (PNs), which are benign peripheral nerve sheath tumors that grow 
along the nerves [Korf, 1999; Ferner et al., 2007]. PNs and other physical manifestations of NF1 
can result in severe and chronic pain. PNs may cause nerve [Citak et al., 2008], airway, and 
spinal cord compression, leg length discrepancies, and scoliosis [Kim et al., 2009]. Furthermore, 
pain is associated with PNs [Creange et al., 1999; Nguyen et al., 2011], which tend to grow most 
rapidly during childhood [Needle et al., 1997; Dombi et al., 2007]. Pain also may emerge after 
tumor removal [Creange et al., 1999]. Common non-tumor physical manifestations causing pain 
include skeletal complications [Elefteriou et al., 2009] and headaches [Creange et al., 1999; 
DiMario and Langshur, 2000]. 
 
Despite the potential for pain in the pediatric NF1 population, limited studies have focused on 
assessing the prevalence, severity, treatment, or impact of pain, with even fewer investigations of 
youth with PNs. In children with NF1 who have primarily mild to moderate disease severity, 
self-ratings of pain were significantly worse than reference values [Krab et al., 2009], and 
adolescents endorsed having pain for an average of four days during a 2-week period [Garwood 
et al., 2012]. Parents of children with NF1 complications reported significantly higher pain 
ratings on a general quality of life (QOL) scale compared to those without complications 
[Oostenbrink et al., 2007]. In a study including a subset of children with NF1 and PNs, 
approximately 30% of them reported pain [Nguyen et al., 2011]. Chart reviews of a pediatric 
sample enrolled in treatment trials for PNs, typically with large tumors and substantial morbidity, 
indicated that 53% reported the presence of pain [Kim et al., 2009]. Although studies evaluating 
the efficacy of analgesics or other pain management techniques in NF1 are limited, data suggest 
that 12% of children with PNs take narcotics [Kim et al., 2009] and over 70% of children and 
adults with NF1 use prescription pain medications [Creange et al., 1999]. 
 
In addition to the physical manifestations, youth with NF1 exhibit learning problems and 
cognitive deficits [Hofman et al., 1994; Koth et al., 2000; Hyman et al., 2005], and they display 
social-emotional difficulties, including higher rates of internalizing and externalizing disorders 
[Johnson et al., 1999; Barton and North, 2004; Graf et al., 2006; Martin et al., 2012], fewer 
friends [Barton and North, 2004; Noll et al., 2007], and more social problems [Dilts et al., 1996; 
Johnson et al., 1999; Barton and North, 2004] compared to normative samples [Barton and 
North, 2004; Graf et al., 2006; Martin et al., 2012] or their unaffected siblings [Dilts et al., 1996; 
Johnson et al., 1999]. While mechanisms for these functional problems have not been fully 
explored, the physical manifestations of NF1, along with cognitive and environmental factors, 
have been linked to social-emotional [Barton and North, 2004; Martin et al., 2012] and QOL 
outcomes [Wolkenstein et al., 2001; Graf et al., 2006; Krab et al., 2009]. Due to its relationship 
to disease severity [Page et al., 2006], pain may play a contributory role as well [Oostenbrink et 
al., 2007]. A recent study in adolescents with NF1 found that emotional functioning predicted 
overall QOL while physical complications, such as pain, predicted functional disability 
[Garwood et al., 2012]. These studies suggest that pain and its impact in NF1 may be best 
understood and treated within a biopsychosocial model, which conceptualizes pain as “the result 
of the dynamic interaction between physiological, psychological, and social factors” [Gatchel et 
al., 2007]. Thus, multiple factors can interact with physical pain to modulate its effect on daily 
functioning and QOL. While associations between various factors in this model have been 
demonstrated in other pediatric pain populations [Miro et al., 2009; Nieto et al., 2012], such 
research is needed in youth with NF1, including those with PNs who may have more severe 
disease complications. Measuring the impact of pain on daily functioning in children and 
understanding its relationship to the disease and other factors is critical for effective medical and 
psychological treatment of this complex disorder. Thus, the aims of this study were to (1) assess 
the degree to which pain interferes with daily functioning (pain interference); (2) describe the 
prevalence and type of pain medications used for treatment; and (3) examine the relationships 
between pain interference, disease factors, social-emotional functioning, and QOL in youth with 
NF1 and PNs. Our primary hypothesis was that social-emotional factors contribute to pain 
interference and overall QOL in this population above and beyond disease severity. 
 
Materials and Methods 
 
Eligibility Criteria 
Children and adolescents with NF1 and PNs from 6 to 18 years of age, who were enrolled on a 
natural history protocol at the National Cancer Institute (NCI) and completed the designated 
comprehensive psychological assessment, were eligible for this pain sub-study. Eligibility 
requirements for this protocol included a diagnosis of NF1 according to the NIH Consensus 
Conference criteria [Stumpf et al., 1988] or a confirmed NF1 germline mutation with analysis 
performed in a CLIA-certified laboratory. Sixty-four enrolled patients were within the target age 
range and had a PN. Of these, three children did not participate in the psychological assessment 
due to lack of interest by caregivers, and a child with autism was excluded because she could not 
complete the measures reliably. Thus, the final sample consisted of 60 patients with NF1 and 
PNs. 
 
Measures 
Demographic variables 
The primary caregiver (parent or legal guardian) completed a questionnaire assessing basic 
demographic data, such as race and years of parental education, as well as background 
information about the child, including sex, NF1 type (sporadic or familial), medical and 
psychiatric diagnoses, educational and therapeutic services, and pain medications. 
 
NF1 symptom severity 
The same primary caregiver also rated their child's overall NF1 symptoms as mild, moderate, or 
severe based on the presence and severity of tumors, pain, motor deficits, and/or learning 
problems, and the extent to which these symptoms impact activities of daily living using the NF1 
Symptom Severity Scale. The authors slightly modified the original scale by Ablon [1996] to 
include possible effects of PNs on daily functioning, such as pain and problems with mobility, 
posture, and vision. 
 
Total PN volume 
PN volumes were obtained from whole-body Short T1-Inversion Recovery Magnetic Resonance 
Imaging (STIR MRI) using a sensitive and reliable semi-automated technique for detecting 
tumors that are not well-defined [Solomon et al., 2004]. Total tumor burden (TTB) was 
calculated by dividing the sum of each patient's PN volumes by body weight and expressed as a 
percentage to account for the broad age range and variability in body mass [Dombi et al., 2007]. 
The TTB data were positively skewed; therefore, a natural log transformation was conducted, 
resulting in an approximately normal distribution (LogTTB). 
 
Disease-related complications 
The nurse practitioner conducting the history and physical exams completed a rating form of 17 
NF1-related diagnoses and disease complications, such as PNs, scoliosis, spinal fusion, vision 
problems, headaches, seizures, and limb length discrepancy, as previously described [Martin et 
al., 2012]. These ratings were summed to produce a total disease complications severity score, 
ranging from 0 to 17. 
 
Pain interference and quality of life 
Caregivers and adolescents completed the Impact of Pediatric Illness (IPI) Scale, a general QOL 
scale that assesses the effects of pediatric chronic illness on the domains of adaptive, emotional, 
physical, and cognitive functioning. It includes a parent proxy-report form for primary caregivers 
of children ages 6–18 years and parallel self-report forms for adolescents ages 10–18 years and 
adults ages 18 years and older. Items are rated on a 5-point Likert scale (1–5; “not at all” to “a 
lot”). To compute the total score, negative items were reversed, individual item ratings (equally 
weighted) were transformed to a scale of 0–100, and the mean was calculated. Higher mean total 
scores indicate better QOL. 
 
The IPI Scale is reliable and valid in NF1 [Wolters et al., 2010; Wolters et al., 2013]. Internal 
consistency of the total scale for both the parent and adolescent forms is good (coefficient α 
reliability estimates were 0.91 and 0.84, respectively). Children with mild NF1 symptoms as 
rated by parents had significantly higher parent proxy and self-report mean total IPI Scale scores 
compared to children with moderate/severe NF1 symptoms, demonstrating construct validity. 
 
Pain interference was assessed by one item on the IPI Scale forms that asks the extent to which 
the individual experiences pain that interferes with his/her daily functioning (“My child has pain 
that interferes with his/her daily functioning” or “I have pain that keeps me from doing what I 
want”). High scores on this item indicate greater pain interference. 
 
Social-emotional functioning 
The anxiety, depression, and withdrawal subscales of the Behavior Assessment System for 
Children-2nd Edition [Reynolds and Kamphaus, 2004] Parent Rating Scale (BASC-II-P) were 
chosen a priori to assess the social-emotional functioning of the children and adolescents, ages 
6–18 years, by parent report for this sub-study. The anxiety, depression, and social stress 
subscales of the BASC-II-Self-Report (BASC-II-SR), which assess similar domains to the parent 
form, were chosen a priori to assess the self-rated social-emotional functioning of the 
adolescents, ages 10–18 years, who also completed the self-report IPI Scale. For both measures, 
raw scores are converted to T-scores (mean = 50; SD = 10). Scores between 60 and 69 are 
considered in the “at risk” (AR) range, and scores of 70 or higher are in the “clinically 
significant” (CS) range. 
 
Procedures 
The NF1 Natural History protocol, a longitudinal study designed to characterize both tumor and 
non-tumor manifestations of the disease, was approved by the NCI Institutional Review Board. 
Referrals came from physicians primarily around the United States or from primary caregivers 
who obtained information about the study from the internet or other sources. Prior to enrollment, 
an investigator obtained informed consent from the child's primary caregiver or adult patient and 
minor assent from children ages 7–17 years. During multi-day outpatient clinic visits, 
participants completed detailed multidisciplinary evaluations including a comprehensive 
psychological evaluation while primary caregivers completed the parent questionnaires. A nurse 
practitioner conducted standardized history and physical exams. The children also underwent a 
whole body STIR MRI scan to assess total tumor burden. 
 
Statistical Analyses 
Descriptive statistics were computed to summarize the demographic and medical data as well as 
pain interference ratings for the total sample and various subgroups including age and sex. 
Analyses of variance (ANOVAs) were conducted to compare the pain severity ratings between 
different subgroups such as young versus older age groups, male versus female, and patients 
taking pain medications on a regular basis versus not taking pain medications. Using ANOVAs 
with repeated measures, caregiver and self-report ratings were compared in the 40 caregiver–
adolescent pairs on the pain interference and overall QOL measures, which consist of parallel 
items, but not on the BASC-II parent and self-report forms that contain different items. 
 
Pearson product moment correlations were calculated in order to estimate the bivariate 
relationships between pain interference, social-emotional functioning, disease variables, and 
quality of life. These correlations were examined within the various caregiver-rated measures 
and also within the various self-reported measures but not between the caregiver and self-report 
measures. To determine the extent to which biopsychosocial factors predict pain interference and 
overall QOL, standard multiple regression analyses were conducted. Since the interaction of both 
physiological and psychological factors may impact the effects of pain on daily functioning, the 
predictor variable with the most significant bivariate correlation was selected from each of the 
biopsychosocial domains assessed (e.g., disease severity and social-emotional functioning) and 
entered into the multiple regressions. To specifically explore the role of social-emotional factors 
as mediators of the relationship between pain interference and QOL, the Sobel test [Lockhart et 
al., 2011] and bootstrapping procedure [Hayes, 2009] were conducted. For all these analyses, the 
pain interference item was not included in the total IPI Scale score; deleting this one item did not 
change the internal consistency of the total scale appreciably for either the adolescent or parent 
form. Since this is an exploratory study investigating possible relationships between these 
domains and a limited number of variables were selected for various analyses, α was set at 0.05. 
 
Results 
 
Demographic Variables 
The total sample consisted of 60 youths with NF1 and PNs, ages 6.3–18.8 years (mean 
age = 12.7 years; SD = 3.6). The demographic characteristics of the total sample, including the 
adolescent (n = 42) and child (n = 18) subgroups, are listed in Table I. Missing data included one 
Parent IPI Scale for an 18-year old whose caregiver did not attend his clinic visit, one Adolescent 
IPI Scale that inadvertently was not administered to a 13-year old, and one tumor volume for a 
12-year old who did not have a baseline whole body MRI scan. Thus, 59 youths had Parent IPI 
Scale data, including the pain interference item, and 41 adolescents, ages 10.6–18.8 years (mean 
age = 14.5 years; SD = 2.4) had self-report IPI Scale data. The 59 caregivers who completed the 
measures about their child's pain and behavior consisted of 44 mothers (75%), 12 fathers (20%), 
and 3 other legal guardians (5%). No significant relationships were found between any of the 
demographic variables (child's age, sex, parent's years of education, NF1 type) and the 
caregivers’ ratings of their child's pain interference, overall QOL, and three social-emotional 
subscales, or the disease variables (LogTTB, number of complications). Similar negative 
findings were found for the child's self-report except on the Anxiety subscale, which was rated 
higher for children with familial versus sporadic NF1 (F = 5.81; P < 0.05); however, the mean T-
scores of both groups were within normal limits (53.9 vs. 47.8, respectively). 
 
 
 
Ratings of Pain Interference 
Children of all ages, from 6 to 18 years, had caregiver ratings indicating that pain was interfering 
with their daily activities to some degree. Seventy-three percent (43 out of 59) of caregivers rated 
that pain interfered “a little” to “a lot” with their child's daily functioning in the past month, 
which was not significantly different between children (83%; 15 out of 18) and adolescents 
(68%; 28 out of 41) (X2 = ns). By self-report, 59% (24 out of 41) of the adolescents rated having 
pain that interfered “a little” to “a lot” with their functioning in the past month. Table II presents 
the breakdown of the caregivers’ and adolescents’ pain interference ratings. 
 
 
 
When examining the 40 caregiver–adolescent pairs, the caregivers’ ratings of their child's pain 
interference (mean = 2.45; SD = 1.2; range = 1–5) did not differ significantly from the 
adolescents’ self-report ratings (mean = 2.18; SD = 1.2; range = 1–5; F = 2.81; P = 0.10). There 
also was no significant difference between the caregivers’ ratings of pain interference between 
the child and adolescent IPI Scale age groups (2.44 vs. 2.42, respectively; F =.01; P = 0.92). 
When comparing disease severity groups, pain interference was significantly higher in youth 
with moderate/severe NF1 disease severity compared to those with mild disease severity, by both 
proxy (2.8 vs. 1.5; F = 21.22; P < 0.0001) and self-report (2.5 vs. 1.4; F = 8.87; P = 0.005). 
 
Pain Medication 
Parents reported that 33% (20/60) of all the participants, including 27% of the children (5/18) 
and 36% of the adolescents (15/42), were taking pain medication on a regular basis. Of those, 
10% (n = 2) were taking only over-the-counter (OTC) pain relievers regularly, such as ibuprofen 
or acetaminophen, while 90% (n = 18) were taking prescription pain medications or a 
combination of prescription and OTC pain medications. As listed in Table III, a wide variety of 
prescription pain medications were reported. Despite taking pain medication on a regular basis, 
pain was rated as interfering with functioning to at least some degree by 93% (14/15) of these 
adolescents and 100% (20/20) of their caregivers. 
 
 
 
Disease Characteristics 
As obtained from the whole body MRI scans, the mean total PN volume was 1,393 ml 
(SD = 1,919; range = 4–12,975) and the mean TTB (expressed as percent of body weight) for the 
total sample was 3.61% (SD = 4.26; range = 0.01–25.02). After the log transformation, the mean 
LogTTB was 0.43 (SD = 1.70; range = −4.61 to 3.22). Based on the nurse practitioner's 
assessment, the mean number of disease complications was 4.6 (SD = 1.6) with a range of 2–9. 
The most common disease complications besides PNs (100%) were spinal neurofibromas (90%), 
scoliosis (58%), visual impairments (62%), and headaches (33%). 
 
Quality of Life and Social-Emotional Functioning 
In the 40 caregiver-adolescent pairs, the caregivers’ ratings of their children's overall QOL (mean 
total IPI score = 68.7; SD = 12.7; range = 45.4–92.1) were not significantly different from the 
adolescents’ self-report ratings (mean total IPI score = 68.4; SD = 11.2; range = 48.0–87.5; 
F = 0.04, ns). Compared to youth with moderate/severe NF1 symptoms, those with mild NF1 
symptoms had higher total IPI scores as rated by both caregivers (n = 59; 64.2 vs. 79.2; F = 29.5, 
P < 0.0001) and adolescents (n = 41; 65.3 vs. 74.8; F = 7.87, P < 0.01), indicating better overall 
QOL in children with less severe symptoms. 
 
As rated by caregivers on the BASC-II-P (n = 59), the mean T-scores on the depression (55.3; 
SD = 10.7; range = 37–79), anxiety (53.0; SD = 11.1; range = 33–86), and withdrawal (53.1; 
SD = 10.5; range = 36–79) subscales were within normal limits. However, 32% of scores on the 
depression subscale, 20% of scores on the anxiety subscale, and 29% of the scores on the 
withdrawal subscale were in the at risk/clinically significant (AR/CS) range. As rated by the 
adolescents (ages 8–18 years; n = 47) on the BASC-II-SR, mean T-scores on the depression 
(49.6; SD = 8.9; range = 40–82), anxiety (50.7; SD = 9.0; range = 34–70), and social stress (48.1; 
SD = 8.3; range = 34–75) subscales were within normal limits. However, 8.5% of the scores on 
the depression subscale, 19% of scores on the anxiety subscale, and 8.5% of the scores on the 
social stress subscale were in the AR/CS range. 
 
Variables Associated With Taking Pain Medication 
Participants who took pain medication on a regular basis had significantly higher mean caregiver 
proxy-report (3.30 vs. 1.97; F = 28.07, P < 0.0001) and adolescent self-report (3.3 vs. 1.5; 
F = 39.34, P < 0.0001) ratings of pain interference compared to those who did not take such 
medication regularly. Children taking regular pain medication also had poorer overall QOL (62.0 
vs. 72.8; F = 11.77, P < 0.01) and more symptoms of depression (60.3 vs. 52.9, F = 6.29, 
P < 0.05) and anxiety (57.9 vs. 50.5, F = 6.33, P < 0.05) as rated by caregivers, as well as poorer 
self-rated QOL (60.2 vs. 75.6; F = 18.79, P < 0.0001), than those not taking pain medication. 
 
When examining disease variables, LogTTB was not significantly different between children 
taking pain medication regularly and those who were not (.87 vs. 0.21; F = 2.01, P = 0.16). The 
mean number of disease complications tended to be higher in children taking pain medications 
but not significantly so (5.1 vs. 4.3; F = 3.35; P = 0.07). 
 
Relationship of Disease Severity and Social-Emotional Functioning to Pain Interference 
As shown in Table IV, higher LogTTB, but not the number of disease complications, was 
significantly related to higher pain interference as rated by caregivers. Neither measure of 
disease severity was related to the adolescent self-report pain interference ratings. More social-
emotional problems in the selected subscales on both the BASC-II-P and BASC-II-SR were 
significantly associated with greater pain interference. 
 
 
 
Relationship of Pain Interference, Disease Variables, and Social-Emotional Functioning to 
Overall QOL 
Also shown in Table IV, less pain interference and better social-emotional functioning in the 
selected domains were associated with better overall QOL (without the pain interference item) as 
rated by both the caregivers and adolescents. Fewer NF1 disease complications were 
significantly related to better proxy-reported QOL while the relation to self-reported QOL was a 
non-significant trend (r = 0.29, P = 0.07). 
 
Multiple Regression Results 
The results of both the caregiver and adolescent multiple regression models examining the extent 
to which variables of disease severity and social-emotional functioning predict degree of pain 
interference are presented in Table V. For the caregiver ratings, the model consisting of their 
child's overall tumor burden and anxiety was significant (F = 9.15, P < 0.001; Adj R2 = 0.22) and 
predicted 22% of the variance in pain interference. Both predictor variables accounted for a 
significant amount of unique variance. For the adolescents, the model including total disease 
complications and self-reported anxiety predicted self-reported pain interference (F = 7.34, 
P < 0.01; Adj R2 = 0.26) and accounted for 26% of the variance; only anxiety was a significant 
predictor. 
 
 
The results of both the caregiver and child models examining the extent to which pain 
interference, disease severity, and social-emotional functioning predict overall QOL are 
presented in Table VI. For the caregivers’ ratings, the model consisting of their children's pain 
interference, disease complications, and depressive symptoms was significant (F = 26.8, 
P < 0.0001; Adj R2 = 0.57) and predicted 57% of the variance in overall QOL. Each of the 
predictor variables accounted for a significant amount of unique variance. For the adolescents’ 
ratings, the model including pain interference, disease complications, and social stress was 
significant (F = 20.20, P < 0.0001; Adj R2 = 0.62), and predicted 62% of the variance in overall 
QOL; only self-reported social stress and pain interference accounted for significant amounts of 
unique variance. 
 
 
 
Exploratory Testing for Indirect Effects 
As shown in Figures 1 and 2, pain interference was significantly associated with overall QOL 
(path c’) and with proxy-report of depressive symptoms and self-report of social stress (path a). 
When controlling for pain interference, social-emotional problems were significantly associated 
with QOL (path b). Furthermore, tests of the indirect effects of pain interference on overall QOL 
through social-emotional functioning (proxy-rated depression and self-rated social stress) were 
significant according to the Sobel test (t = −2.1, P < 0.001; t = −2.3, P < 0.05; respectively) and 
bootstrapping analyses (95%CIs: −3.37 to −1.2, estimated effect of depressive symptoms = −2.1; 
95%CIs: −3.3 to −0.78, estimated effect of social stress = −1.76), and pain interference remained 
significantly related to QOL (path c’). These results suggest that social-emotional problems 
partially mediate the effects of pain interference on overall QOL. Thus, children who have 
greater pain interference have poorer QOL, in part, because of the relationship between social-
emotional difficulties and pain interference. 
 
 
 
 
Discussion 
 
In this sample of youth with NF1 and PNs, ages 6–18 years, a substantial portion (73%) of 
caregivers indicated that pain interferes with their child's everyday functioning, ranging from “a 
little” to “a lot,” while the majority of adolescents (59%) self-rated such levels of pain 
interference. One third of these youth regularly take pain medications including prescription 
drugs, yet despite such medication use, almost all of this subset continue to report that pain 
interferes with everyday functioning. Thus, pharmacologic treatment does not appear to be 
controlling their pain sufficiently. Furthermore, the children and adolescents regularly taking 
pain medication have significantly poorer overall QOL and exhibit more symptoms of depression 
and anxiety, but not significantly greater disease severity, than those not taking pain medication. 
Thus, managing and coping with pain are critical but unmet needs for these youth. Although 
other studies have reported the presence of pain in up to 53% of children with NF1 and PNs 
[Kim et al., 2009; Nguyen et al., 2011], this is the first published study to our knowledge that 
assessed prospectively the degree of pain interference in this population. 
 
Consistent with our hypothesis and the biopsychosocial model, greater pain interference was 
associated with a variety of factors including more internalizing problems, such as depression, 
anxiety, and socialization difficulties, greater PN tumor burden, and poorer overall QOL. 
Furthermore, social-emotional functioning, particularly anxiety, is a primary predictor of pain 
interference that accounts for a significant amount unique variance. In addition, pain interference 
and social-emotional factors are significant predictors of overall QOL; in the caregiver analyses, 
the number of disease complications also contributes to QOL but to a lesser extent than the other 
variables. Importantly, social-emotional problems (caregiver-rated depressive symptoms and 
self-rated social stress) partially mediated the effects of pain interference on overall QOL. 
Related research in children with other chronic health conditions, such as cystic fibrosis, sickle 
cell disease, and juvenile idiopathic arthritis, have described similar relationships between pain, 
social-emotional functioning, and impact on daily living activities [Palermo et al., 2006; Barakat 
et al., 2008; Connelly et al., 2012]. These studies, as well as the current results, highlight the 
complex interaction of physical pain and affective states as conceptualized by the 
biopsychosocial model and supported by neurobiological research [Gatchel et al., 2007; Lumley 
et al., 2011]. Neuroimaging studies have demonstrated brain pathways that link pain and 
emotional regulation while an imbalance of various neurotransmitters may contribute to the 
chronic pain state as well [Gatchel et al., 2007; Garland, 2012]. Importantly, the current results 
suggest that pain interference as well as social-emotional functioning should be targets for 
intervention in NF1, both in terms of pharmacologic treatment and psychological therapies to 
help address concurrent physical and emotional symptoms. The interdependence of these factors 
indicate that treatment for chronic pain must involve interdisciplinary and multi-modal therapies, 
including mindfulness-based and other mind-body techniques, in order to be the most effective 
[Gatchel et al., 2007; Zeidan et al., 2012]. 
 
Pain interference in this sample of youth with NF1 and PNs was not significantly affected by 
age, gender, SES, or familial versus sporadic NF1. While healthy samples have reported a higher 
prevalence of pain and pain interference in older versus younger adolescents [Roth-Isigkeit et al., 
2005] and females [Fouladbakhsh et al., 2012], such age and sex differences in disease-related 
pain and functional disability typically have not been described in youth with NF1 or other 
chronic medical conditions [Koh et al., 2005; Kritzberger et al., 2011; Garwood et al., 2012; 
Lundberg et al., 2012]. Socioeconomic status (SES), measured by years of parental education in 
the current study, was not related to pain interference. However, higher SES was related to less 
bodily pain [Krab et al., 2009] and better QOL in various domains [Oostenbrink et al., 2007] in 
other studies of children with NF1. These discrepant results may be related to the various 
outcomes assessed and different samples; the current study included only youth with PNs, and 
the size of the PN tumors was associated with pain interference but not parental level of 
education (r = −0.12; ns). Studies in children with other medical conditions have found that 
higher SES is associated with lower pain [King et al., 2011] and better clinical outcomes 
[Quittner et al., 2010]; thus, SES should be considered in research exploring factors related to 
such outcomes in NF1 as well. Familial NF1 has been related to better QOL in some domains in 
children, but not specifically pain [Graf et al., 2006; Oostenbrink et al., 2007; Krab et al., 2009], 
consistent with the current study that did not find a difference in pain interference between 
familial and sporadic NF1. 
 
When comparing caregiver and self-reports, there were no significant differences in the ratings 
of pain interference or overall QOL. However, previous research assessing QOL in pediatric 
medical conditions consistently have found differences between parent and child reports [Upton 
et al., 2008; Lundberg et al., 2012]. In NF1 studies, the agreement between parents and their 
children have ranged from low to high, with the lowest concordance being in the behavioral 
domains and the highest on the physical domains [Graf et al., 2006; Krab et al., 2009]. It is 
possible that differences may be found when examining the specific domains of QOL in children 
with NF1 and PNs, which was not the focus of the current study. In the regression analyses, there 
were some differences in the variables found to be the primary predictors of the caregivers’ and 
patients’ data, which supports the use of self-report measures to understand the adolescents’ 
perceptions and guide treatment planning. 
 
In examining the relationships of pain interference and QOL to disease factors, greater proxy-
reported pain interference was related to larger PN tumor volume but not number of disease 
complications. In contrast, proxy-reported QOL was related to the number of NF1 disease 
complications but not to tumor burden. Thus, larger PNs may be one of the main disease 
manifestations contributing to pain that interferes with daily functioning in these youth, while 
their multiple disease complications have more of an impact on overall QOL. Other reports have 
found that individuals with PNs report the presence of pain [Citak et al., 2008; Kim et al., 2009; 
Nguyen et al., 2011] and that higher bodily pain and poorer QOL were related to parent 
perceptions of the presence of NF1 complications [Graf et al., 2006; Oostenbrink et al., 2007]. 
 
Several limitations of this study should be considered when interpreting the results. First, pain 
interference was assessed using a single item from a general QOL scale for children with chronic 
illnesses. This question inquires only about the extent to which pain interferes with overall daily 
functioning and does not assess the impact of pain on specific activities or the frequency and 
intensity of pain, which would provide a more comprehensive assessment. Furthermore, the 
response period of the scale was over the past month whereas measures assessing pain during a 
shorter time period (e.g., in the past week or in real-time) may provide more accurate data. In 
addition, the study was cross-sectional; thus, the results of the mediational analyses are 
considered exploratory since longitudinal data are required to make more definitive statements of 
mediation [Kraemer et al., 2008]. Finally, the generalizability of our findings is limited by our 
specific patient population: the sample consisted only of youth with PNs, many of whom were 
referred to the NCI for PN treatment trials and may have larger tumors and more severe 
complications than other children with NF1. 
 
Despite these limitations, the current study extends the literature in several ways. First, it 
prospectively assessed the degree of pain interference in children and adolescents with NF1 and 
PNs to provide initial yet important information about the impact of pain on their everyday 
functioning. In addition, it used quantitative methods of disease severity and specific measures of 
social-emotional functioning to investigate the relationships of these factors with pain 
interference and QOL. This study indicated that social-emotional problems are unique predictors 
of pain interference and QOL, and partially mediate the relationship between these variables; 
thus, interventions for these youth should teach strategies to increase emotional awareness and 
improve their affective states in conjunction with medical therapies. Importantly, the current 
study applied theoretical and mediational models to begin to explain and organize the multiple 
factors that may influence the experience and impact of pain in NF1. The findings support the 
use of the biopsychosocial model to design future research and guide the treatment of pain in this 
population. 
 
It is recommended that future studies continue to assess various aspects of pain in NF1, including 
location, source, frequency, triggers, and pain quality, which will help to guide treatment efforts. 
It will also be useful to investigate whether pain in this population is associated with 
disturbances in specific activities of daily living, such as school attendance [Dick and Pillai, 
2010], participation in hobbies [Roth-Isigkeit et al., 2005], and sleep [Roth-Isigkeit et al., 2005; 
Citak et al., 2008]. In addition, studies are needed to understand the contributions of other 
variables in the biopsychosocial model, such as environmental stress, family functioning, coping 
styles, and cognitive processes, which may impact pain interference and QOL in medically ill 
children [Gatchel et al., 2007; Barakat et al., 2008; Lewandowski et al., 2010]. Finally, 
longitudinal studies are required to reveal how these biopsychosocial variables change over time 
in NF1 and determine how they interact with one another and influence outcomes throughout 
development using mediational analyses [Kraemer et al., 2008; Nieto et al., 2012]. Most 
importantly, psychological interventions should be developed and evaluated for children and 
adolescents affected by NF1 and PNs that will address their social-emotional difficulties and 
help them cope with their pain as a means to improve their QOL. 
 
Conclusions 
 
Pain interferes with the daily functioning of the majority of children and adolescents with NF1 
and PNs, including those regularly taking pain medication. Total tumor volume and social-
emotional problems predict pain interference while disease complications, pain interference, and 
social-emotional problems predict overall QOL. These results highlight the complex interactions 
between the physical manifestations of pain and psychological functioning in this population and 
target areas for future research and interventions that apply the biopsychosocial model. The 
development and investigation of therapeutic interventions that utilize a multidisciplinary 
approach and include psychological interventions need to be a priority for youth with NF1 and 
PNs. 
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